Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non–Small Cell Lung Cancer

Abstract

Background The aim of this study was to explore the feasibility of surgery after two induction cycles of cisplatin-docetaxel followed by concomitant 40 Gy chemoradiation in the treatment of initially unresectable stage III non–small cell lung cancer (NSCLC; TAXCIS protocol), and to evaluate overall survival (OS) and recurrence-free survival (RFS) and recurrence risk factors over a larger cohort of patients with a subgroup analysis of patients treated by pneumonectomy.

Methods Between 2004 and 2014, a total of 37 patients were treated. Only patients responding to induction treatment were included.

Results We operated on 32 stage IIIA and 5 stage IIIB patients. We performed 12 pneumonectomies, 1 bilobectomy, and 23 lobectomies. Status ypT0N0 was obtained for 35% of the patients. Surgery was considered R0 in 86% of the cases. Postoperative morbidity was 21.6% with a mortality of 10.8% (25% after pneumonectomy). OS was 50% at 5 years. The median RFS was 50 months. RFS was 47% at 5 years. Local or locoregional recurrence was diagnosed in 10.8% of the patients, and distant metastasis in 35.1%. Recurrence risk factors were pneumonectomy (p = 0.001) and a histologically incomplete response (p = 0.04).

Conclusion The TAXCIS protocol followed by surgery is feasible for initially unresectable NSCLC stage IIIA and B patients. Benefit was noted in responding lesions with better OS and PFS, except after pneumonectomy.

Keywords

lung cancer - radiation therapy - chemotherapy

• References

• 1 Bezjak A, Temin S, Franklin G. , et al. Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. J Clin Oncol 2015; 33 (18) 2100-2105
• 2 Le Chevalier T, Arriagada R, Quoix E. , et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994; 10 (Suppl. 01) S239-S244
• 3 Poudenx M, Bondiau PY, Chamorey E. , et al. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial. Oncology 2012; 83 (06) 321-328
• 4 Eisenhauer EA, Therasse P, Bogaerts J. , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
• 5 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240 (02) 205-213
• 6 Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15 (01) 4-9
• 7 Albain KS, Rusch VW, Crowley JJ. , et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13 (08) 1880-1892
• 8 Krasna MJ. COUNTERPOINT: Pneumonectomy after chemoradiation: the risks of trimodality therapy. J Thorac Cardiovasc Surg 2009; 138 (02) 295-299
• 9 Albain KS, Swann RS, Rusch VW. , et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374 (9687): 379-386
• 10 DeCamp MM, Rice TW, Adelstein DJ. , et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126 (01) 17-27
• 11 Eberhardt W, Gauler T, LePechoux C. , et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer 2013; 82 (01) 83-89
• 12 Edelman MJ, Suntharalingam M, Burrows W. , et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 2008; 86 (03) 903-910
• 13 Friedel G, Budach W, Dippon J. , et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010; 28 (06) 942-948
• 14 Girard N, Mornex F, Douillard JY. , et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer 2010; 69 (01) 86-93
• 15 Grunenwald DH, André F, Le Péchoux C. , et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001; 122 (04) 796-802
• 16 Hainsworth JD, Gray JR, Litchy S. , et al. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer. Clin Lung Cancer 2004; 6 (01) 33-42
• 17 Hehr T, Friedel G, Steger V. , et al. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol. Int J Radiat Oncol Biol Phys 2010; 76 (05) 1376-1381
• 18 Katakami N, Okazaki M, Nishiuchi S. , et al. Induction chemoradiotherapy for advanced stage III non-small cell lung cancer: long-term follow-up in 42 patients. Lung Cancer 1998; 22 (02) 127-137
• 19 Katakami N, Tada H, Mitsudomi T. , et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 2012; 118 (24) 6126-6135
• 20 Lim HJ, Lee HY, Lee KS. , et al. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery. Cancer Chemother Pharmacol 2015; 75 (01) 77-85
• 21 Mathisen DJ, Wain JC, Wright C. , et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1996; 111 (01) 123-131 , discussion 131–133
• 22 Sher DJ, Fidler MJ, Liptay MJ, Koshy M. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer 2015; 88 (03) 267-274
• 23 Shien K, Toyooka S, Soh J. , et al. Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. Mol Clin Oncol 2015; 3 (03) 706-712
• 24 Shintani Y, Funakoshi Y, Inoue M. , et al. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2012; 18 (06) 530-535
• 25 Stamatis G, Eberhardt W, Stüben G, Bildat S, Dahler O, Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999; 68 (04) 1144-1149
• 26 Suntharalingam M, Paulus R, Edelman MJ. , et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2012; 84 (02) 456-463
• 27 Thomas M, Rübe C, Semik M. , et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999; 17 (04) 1185-1193
• 28 Toyooka S, Kiura K, Shien K. , et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg 2012; 15 (06) 954-960
• 29 Trodella L, Granone P, Valente S. , et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 2004; 15 (03) 389-398
• 30 Uramoto H, Akiyama H, Nakajima Y. , et al. The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. Case Rep Oncol 2014; 7 (03) 700-710
• 31 Barnett SA, Rusch VW, Zheng J. , et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol 2011; 6 (09) 1530-1536